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Decreased serotonin (5-HT) function is associated with numerous cognitive and affective
disorders. Women are more vulnerable to these disorders and have a lower rate of
5-HT synthesis than men. Serotonergic neurons in the dorsal raphe nucleus (DRN)
are a major source of 5-HT in the forebrain and play a critical role in regulation
of stress-related disorders. In particular, polymorphisms of tryptophan hydroxylase-2
(TpH2, the brain-specific, rate-limiting enzyme for 5-HT biosynthesis) are implicated in
cognitive and affective disorders. Administration of 17β-estradiol (E2), the most potent
naturally circulating estrogen in women and rats, can have beneficial effects on cognitive,
anxiety-like, and depressive-like behaviors. Moreover, E2 increases TpH2 mRNA in
specific subregions of the DRN. Although conjugated equine estrogens (CEE) are a
commonly prescribed estrogen component of hormone therapy in menopausal women,
there is a marked gap in knowledge regarding how CEE affects these behaviors and
the brain 5-HT system. Therefore, we compared the effects of CEE and E2 treatments
on behavior and TpH2 mRNA. Female Sprague-Dawley rats were ovariectomized,
administered either vehicle, CEE, or E2 and tested on a battery of cognitive, anxiety-like,
and depressive-like behaviors. The brains of these animals were subsequently analyzed
for TpH2mRNA. Both CEE and E2 exerted beneficial behavioral effects, although efficacy
depended on the distinct behavior and for cognition, on the task difficulty. Compared to
CEE, E2 generally had more robust anxiolytic and antidepressant effects. E2 increased
TpH2 mRNA in the caudal and mid DRN, corroborating previous findings. However, CEE
increased TpH2 mRNA in the caudal and rostral, but not the mid, DRN, suggesting
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that distinct estrogens can have subregion-specific effects on TpH2 gene expression.
We also found differential correlations between the level of TpH2 mRNA in specific DRN
subregions and behavior, depending on the type of behavior. These distinct associations
imply that cognition, anxiety-like, and depressive-like behaviors are modulated by unique
serotonergic neurocircuitry, opening the possibility of novel avenues of targeted treatment
for different types of cognitive and affective disorders.
Keywords: spatial, cognition, learning and memory, serotonin, TpH2, Premarin, estrogen, mood
INTRODUCTION
Anxiety and depression are prevalent and highly comorbid with
cognitive impairment (Lenze and Wetherell, 2011). In particular,
women are more vulnerable to both cognitive and affective
disorders than men (Lenze and Wetherell, 2011). The dynamic
nature of circulating ovarian hormones, such as estrogens, may
contribute to the higher rates of these disorders in women
compared to men. Evidence suggests that changing or low levels
of estrogens in women during peri- and post- menopause are
associated with cognitive decline and affective disorders (Arpels,
1996; Lenze and Wetherell, 2011). These symptoms are often
effectively treated by estrogen-including hormone therapy (HT;
Best et al., 1992; Halbreich et al., 1995; Sichel et al., 1995; Gregoire
et al., 1996; Bimonte-Nelson et al., 2010).
Over the years, concerted efforts have been made to elucidate
the effects of HT on cognition andmood. Accumulating evidence
in humans and animal models demonstrates that estrogens can
have a protective role. Specifically, benefits of 17β-estradiol (E2),
the most potent naturally circulating estrogen, on cognition, as
well as anxiety and depression, have been realized in both clinical
and preclinical settings (Caldwell and Watson, 1952; Nomikos
and Spyraki, 1988; Luine and Rodriguez, 1994; Daniel et al.,
1997, 2005; Bimonte and Denenberg, 1999; Fader et al., 1999;
Korol and Kolo, 2002; Markham and Juraska, 2002; Estrada-
Camarena et al., 2003; El-Bakri et al., 2004; Feng et al., 2004; Lund
et al., 2005; Bimonte-Nelson et al., 2006; Hiroi and Neumaier,
2006; Hruska and Dohanich, 2007; Talboom et al., 2008). In
women, estrogen-containing HT in the form of conjugated
equine estrogens (CEE; tradename Premarin) has also been
shown to reduce anxiety (Campbell and Whitehead, 1977),
improve mood (Gleason et al., 2015), and enhance cognitive
functions (Campbell and Whitehead, 1977; Ohkura et al., 1995).
While abundant evidence indicates beneficial effects of
estrogens on various measures of cognitive function, anxiety,
and mood, findings are nonetheless contradictory. The most
prominent landmark findings questioning estrogens’ cognitive
enhancing effects were from the Women’s Health Initiative
Memory Study (WHIMS) funded by the National Institutes
of Health. In this study, in women, CEE was found to
increase the risk for probable dementia when taken concurrently
with medroxyprogesterone acetate (Shumaker et al., 2003) and
trended toward increasing the risk of probable dementia andmild
cognitive impairment when taken alone (Shumaker et al., 2004).
Following this pivotal study signifying adverse effects of CEE,
the use of CEE, particularly with medroxyprogesterone acetate,
dramatically decreased, while bioidentical hormones, including
E2, gained popularity among women (Hersh et al., 2004; Files
et al., 2011; Tsai et al., 2011). CEE is comprised of more than
10 different forms of estrogens, including estrone sulfate (a
weaker form of estrogen compared to E2) as the primary form
of estrogen, and only a minimal level of E2. As such, CEE may
exert distinct effects on cognition and mood compared to that of
E2. An effort has been made recently in a randomized, placebo-
controlled clinical trial, Kronos Early Estrogen Prevention Study
(KEEPS), to compare the cognitive and affective outcomes of
healthy, recently menopausal women with low cardiovascular
risk profiles taking either CEE- or E2- containing HT (Gleason
et al., 2015). The findings from this study indicated that there
were no HT effects on cognition for the hormones tested, and
a differential effect of CEE vs. E2 on mood.
The rodent model has served as an invaluable tool for
studying many factors and variables. Mitigating and controlling
for the confounds of human research including socioeconomic
status, education, age, timing and duration of HT, menopause
status, and endogenous hormone interactions, rodent studies
enable a systematic evaluation of the effects of HT in a controlled
environment. Capitalizing on these advantages, preclinical
studies have demonstrated beneficial effects of E2 using rodent
models of cognition, anxiety, and depression. For instance, in
rodents, E2 administration improved working and reference
memory in various tests of spatial cognition (Luine and
Rodriguez, 1994; Bimonte and Denenberg, 1999; Fader et al.,
1999; Korol and Kolo, 2002; Markham et al., 2002; El-Bakri et al.,
2004; Feng et al., 2004; Daniel et al., 2005; Bimonte-Nelson et al.,
2006; Hruska and Dohanich, 2007; Talboom et al., 2008; Tsai
et al., 2011). In the rodent, E2 also has been shown to decrease
anxiety-like behaviors, as measured by increased center time in
the open field test (OFT; Lund et al., 2005; Hiroi et al., 2006;
Hiroi and Neumaier, 2006) and increased open arm time in the
elevated plus maze (EPM; Nomikos and Spyraki, 1988; Lund
et al., 2005). E2 also decreased immobility in the forced swim test
(FST; Estrada-Camarena et al., 2003;Walf et al., 2004), suggesting
antidepressant activity. Emerging evidence, however, is revealing
a complex interplay of parameters governing hormonal
influences on cognition (Bimonte-Nelson et al., 2010), such as
menopause type (transitional or surgical; Acosta et al., 2009),
time after ovarian hormone loss and age (Gibbs, 2000; Daniel
et al., 2006; McLaughlin et al., 2008; Talboom et al., 2008), mode
and dose of hormone administration (Diaz-Veliz et al., 1991;
Díaz-Véliz et al., 1999; Frick et al., 1995; Packard and Teather,
1997; Rissanen et al., 1999; Holmes et al., 2002; Bimonte-Nelson
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et al., 2004, 2006; El-Bakri et al., 2004; Gresack and Frick, 2004),
and whether estrogen was given alone or in conjunction with a
progestogen component (Bimonte-Nelson et al., 2006; Harburger
et al., 2007; Lowry et al., 2010; Chisholm and Juraska, 2012).
Previous animal studies have also investigated the effects of CEE
on cognition and affect. Our laboratory has demonstrated that
in middle-aged Fischer-344 rats, CEE had beneficial effects on
cognition, although these effects depended on multiple variables,
such as the hormonal status of the rats, specific memory task
used to evaluate cognition, and dosing parameters (Acosta et al.,
2009, 2010; Engler-Chiurazzi et al., 2011). In addition, Frye
and colleagues showed beneficial effects of CEE on cognition
and anxiety-like behaviors in middle-aged Long Evans rats;
however, the effects depended on the reproductive status of the
rats (Frye et al., 2010). To our knowledge, whether CEE impacts
depressive-like measurements in animal models has not been
reported.
While underlying mechanisms for estrogen effects on
cognition, anxiety, and depression are largely unknown, there
are several lines of evidence that underscore the importance of
the brain serotonin (5-HT) system. Notably, postmenopausal
women have decreased serotonergic activity (Halbreich et al.,
1995), which is associated with a higher incidence of cognitive
and affective disorders (Waider et al., 2011). Estrogen treatment
reverses the decreased serotonergic activity in these women
(Halbreich et al., 1995) and ameliorates symptoms of cognitive
and affective disorders (Campbell and Whitehead, 1977; Best
et al., 1992; Ohkura et al., 1995; Arpels, 1996; Gregoire et al.,
1996; Gleason et al., 2015). Studies using positron emission
tomography scans have also shown a decreased rate of 5-HT
synthesis in women compared to men (Okazawa et al., 2000)
and in depressed compared to non-depressed patients (Rosa-
Neto et al., 2004). Animal studies corroborate these findings, as
baseline firing rate of 5-HT neurons in the midbrain dorsal raphe
nucleus (DRN), a major source of 5-HT in the forebrain, is lower
in cycling and ovariectomized (Ovx) female rats compared to that
in male rats (Klink et al., 2002; Robichaud and Debonnel, 2005).
Estrogen stimulates 5-HT activity, as illustrated by increased
serotonergic neurotransmission during pregnancy and following
exogenous E2 treatment (Klink et al., 2002; Robichaud and
Debonnel, 2005). These studies together indicate that decreased
serotonergic function in women contributes to vulnerability to
some forms of cognitive and affective disorders, and that estrogen
administration may ameliorate symptoms by increasing 5-HT
neurotransmission.
Of note, tryptophan hydroxylase-2 (TpH2), a brain-specific
isoform of the rate-limiting enzyme for 5-HT biosynthesis
(Walther and Bader, 2003), has been implicated in the regulation
of cognition, anxiety, and depression (Sun et al., 2004; Nash et al.,
2005; You et al., 2005; Zhang et al., 2005). Previous studies have
shown that E2 increases TpH2 mRNA in specific subregions
of the DRN in Ovx rats (Hiroi et al., 2006), and that this
increase is critical for ameliorating anxiety-like and depressive-
like behaviors (Hiroi et al., 2006, 2011). Collectively, these studies
suggest that the beneficial effects of estrogens are mediated by
enhanced brain 5-HT activity, perhaps via the upregulation of
TpH2 expression in specific subregions of the DRN.
Previous studies exploring the effects of CEE on the DRN
5-HT system are limited. In non-human primates, pioneering
works by Bethea and colleagues have demonstrated that
CEE administration increased TpH1 (the original isoform of
tryptophan hydroxylase) protein levels in the DRN of Ovx adult
macaques (Bethea et al., 2000; Shively et al., 2003). In light of
the recent discovery of a second, brain-specific isoform, TpH2
(Walther and Bader, 2003), and demonstration of a significant
relationship between the behavioral effects of E2 and the level
of TpH2 mRNA in distinct subregions of the DRN (Hiroi et al.,
2006, 2011; Donner and Handa, 2009), the next critical step is to
examine how CEE impacts TpH2 in the subregions of the DRN.
To date, however, the effects of CEE on TpH2 expression in the
rodent DRN have not been examined, with a noted lack of work
in varied DRN subregions. Comparing the region-specific effects
of CEE vs. E2 on TpH2 may provide insight into the mechanisms
underlying the behavioral effects of these estrogens.
The present study was designed to extend the previous work
from our laboratory showing cognitive effects of CEE and E2
in middle-aged Fischer-344 rats (Bimonte-Nelson et al., 2006;
Talboom et al., 2008; Acosta et al., 2009, 2011; Engler-Chiurazzi
et al., 2011) to a younger age group and a different rat strain by
evaluating the cognitive effects of these estrogens in young adult,
Ovx Sprague Dawley rats. Thus far, none of the aforementioned
preclinical studies have directly compared the effects of CEE
and E2. In addition, to our knowledge, no previous studies have
examined the effects of CEE on depressive-like behaviors or on
DRN TpH2 expression in the rodent model. Therefore, in the
present study, we evaluated and compared the effects of CEE
and E2 administration on TpH2 mRNA expression in the DRN,
and on a battery of cognitive, anxiety-like, and depressive-like
behaviors in Ovx Sprague Dawley rats. The relationship between
TpH2 mRNA and the different types of behaviors were also
analyzed to reveal possible hormone- and subregion- specific
changes in DRN TpH2 that may be important for the evaluated
behaviors.
MATERIALS AND METHODS
Animals
A total of 25 female Sprague Dawley rats purchased from Charles
River Laboratories (Wilmington, Massachusetts) were used for
this study. Animals were pair housed, had access to food and
water ad libitum, and were maintained in a temperature and
humidity controlled environment with a 12-h light/dark cycle.
Animals were 4 months old at maze initiation. All procedures
were approved by the Institutional Animal Care and Use
Committee and adhered to the National Institutes of Health
guidelines.
Ovariectomy and Hormone Manipulations
All animals underwent Ovx surgeries. Animals were anesthetized
with isoflurane (Baxter HealthCare, Deerfield, IL) and bilateral
incisions were made from the dorsal aspect. Ovaries and tips
of uterine horns were ligatured and removed, and muscle and
skin were sutured. Rats received Rimadyl (5 mg/mL/kg) for
pain and saline (2 mL) to prevent dehydration. Twenty-five
Frontiers in Neuroscience | www.frontiersin.org 3 December 2016 | Volume 10 | Article 517
Hiroi et al. Estrogens, Brain Serotonin, and Behavior
days following Ovx, rats were randomly assigned to one of the
following treatment groups: Vehicle (sesame oil, n= 9), CEE (30
µg CEE in sesame oil, n = 8), or E2 (3 µg E2 in sesame oil, n
= 8). One subcutaneous injection (0.1mL volume) was given for
2 consecutive days, followed by 2 days off, and this pattern was
repeated throughout the study until animals were sacrificed. The
doses of CEE and E2 were based on CEE and E2 doses previously
shown to enhance performance on spatial tasks (Talboom et al.,
2008; Acosta et al., 2009, 2011; Engler-Chiurazzi et al., 2011). The
dose of CEE used in the current study was also based on the
daily 0.625mg CEE dose commonly taken by women, and used
in the WHIMS. Given the average female body weight of 70 kg
(www.halls.md), we calculated 0.00893mg CEE/kg body weight.
Based on this dose, in a previous study, we utilized a range of
10–30 µg daily administration of powder, which was 10% CEE
(i.e., 1 µg CEE in a 10 µg dose and 3 µg CEE in a 30 µg dose)
to evaluate cognitive effects in female rats (Acosta et al., 2009;
Engler-Chiurazzi et al., 2011). The highest dose of 30 µg powder
(i.e., 3 µg of CEE specifically) was chosen for this study, as this
dose showed the most beneficial cognitive profile in the prior
work.
The treatment regimen of 2 days on and 2 days off was chosen
based on previous reports showing cognitive effects of CEE in
middle-aged Ovx Fischer-344 rats (Acosta et al., 2009; Engler-
Chiurazzi et al., 2011). We chose this intermittent, pulsatile
regimen over a continuous, tonic regimen as our laboratory
found cognitive enhancements using an identical intermittent
regimen of CEE treatment (Acosta et al., 2009), while a tonic
CEE treatment via an osmotic pump impaired cognition (Engler-
Chiurazzi et al., 2011). This temporal regimen of E2 injection
also has been shown to alter hippocampal plasticity and memory
(Woolley and McEwen, 1993; Korol and Kolo, 2002; McLaughlin
et al., 2008). The present study was designed to extend these prior
findings to a younger age group and a different rat strain, by
evaluating cognition in young adult, Ovx Sprague Dawley rats.
In addition, we sought to compare the cognitive effects of CEE to
that of E2. Finally, we also expanded our study design to include
outcome measures evaluating anxiety-like and depressive-like
behaviors as well as the level of DRN TpH2 gene expression.
Uterine Weights
To confirm Ovx and hormone treatment, uterine tissues were
collected at sacrifice. The uterus was cut between the cervix and
the ligature remaining from Ovx, and was trimmed of all visible
fat. It was immediately weighed to obtain wet weight.
Behavioral Testing
Sixteen days following the initiation of hormone treatment (41
days after Ovx), a series of behavioral tests commenced in
the following order: water radial arm maze (WRAM), Morris
maze (MM), delayed-match-to-sample (DMS), OFT, EPM, and
FST. Figure 1 depicts the timeline of the Ovx surgery, hormone
treatment, and behavioral testing.
Water Radial-Arm Maze
After 16 days of hormone treatment, the eight-arm WRAM was
used to evaluate spatial working and reference memory (Hyde
et al., 1996, 1998; Bimonte and Denenberg, 1999). Working
memory is information requiring updating that is pertinent for a
short time, while reference memory is information that remains
constant over time (Jarrard et al., 1984; Jones, 2002; Bimonte-
Nelson, 2015). The WRAM contained hidden platforms at the
ends of four of the eight arms. Each animal received 1 session
per day for 12 days, with platform locations remaining constant
across all sessions for each animal. A session consisted of 4
trials; in a trial, an animal had 3 min to locate a platform, and
once found, the animal remained on it for 15 sec. The just-
found platform was removed from the maze while the animal
was placed in a heated cage for a 30 sec inter-trial interval (ITI).
This procedure was repeated until all remaining platforms were
found, resulting in 4 trials per day. Because the number of
platformed-arms decreased by 1 on each subsequent trial, the
working memory load increased as trials progressed within a
session.
Errors were quantified using the orthogonal measures of
working and reference memory errors. First and repeated entries
into arms that contained a platform that had been removed
during the session were considered working memory correct
errors (WMC). First entries into arms that never contained a
platform were scored as reference memory errors (RM). Repeat
entries into reference memory arms were scored as working
memory incorrect errors (WMI).
Since animals had no prior experience with the maze on
the first day, Day 1 was considered a training session and was
excluded from analysis of the testing sessions, which were Days
2–12. Testing days were blocked into the acquisition phase (Days
2–7) and the asymptotic phase (Days 8–12), and each type of
error was analyzed separately. Similar blocking methods have
been used for WRAM analyses evaluating ovarian hormones
(Bimonte et al., 2000; Bimonte-Nelson et al., 2003a,b). On Day
13, a 4-h delay was given between trials 2 and 3.
Morris Maze
One day following the end of WRAM testing, the MM was
used to test spatial reference memory. The MM was a round
water-filled container (188 cm diameter) with a hidden platform
remaining in a fixed location throughout testing. Each animal
received 1 session per day for 5 days, with 4 trials per day.
In a trial, an animal had 60 sec to locate the platform after
being placed in one of the four alternating start locations: the
north, south, east, or west wall of the maze. After finding the
platform, the animal remained on the platform for 15 sec and
then was placed into a heated cage until the next trial, with
an approximate ITI of 10 min. This procedure was repeated
for the remaining trials. A video camera was connected to a
tracking system (Ethovision, Noldus Instruments, Wageningen,
The Netherlands), which analyzed the path of each rat. Swim
distance (cm) from the start location to the platform was the
dependent variable.
On the last day, after completion of all trials, a probe trial was
given to test whether the animals spatially localized the platform
location. In the probe trial, animals were allowed to swim for
60 sec in the MM without the platform. Percent swim distance
in the previously platformed (target) quadrant was compared to
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FIGURE 1 | Time course of surgeries, hormone administration, behavioral testing, and sacrifice in the present study. Twenty-five days following Ovx, rats
were randomly assigned to one of the following treatment groups: Vehicle (sesame oil, n = 9), CEE (30 µg CEE in sesame oil, n = 8), or E2 (3 µg E2 in sesame oil, n =
8). One subcutaneous injection (0.1 mL volume) was given for 2 consecutive days, followed by 2 days off, and this pattern was repeated throughout the study until
animals were sacrificed. Sixteen days following the initiation of hormone treatment (41 days after Ovx), a series of behavioral tests commenced in the following order:
water radial arm maze (WRAM), Morris maze (MM), delayed-matched-to-sample (DMS), open field test (OFT), elevated plus maze (EPM), and forced swim test (FST).
One week of rest prior to sacrifice was given to all animals following the last behavioral testing day to minimize any sub-acute stress effects on gene expression.
Animals were sacrificed by decapitation and brains were rapidly removed, flash frozen in 2-methylbutane at −30◦C, and stored at −80◦C until processed for TpH2
mRNA analysis.
percent swim distance in the diagonally opposite quadrant, with
the tenet that animals that had learned the spatial location of the
platform should have the greatest percent of total swim distance
in the target compared to the opposite quadrant.
Delayed-Match-to-Sample
One day following the end of MM testing, the win-stay DMS
place learning task was used to assess spatial working memory
as well as short-term memory retention (i.e., recent memory).
The DMS task had a platform hidden at the end of one of the
four arms. The platform location was the same within a day, but
changed across days. Each animal received 1 session per day for
7 consecutive days, with 6 trials per daily session. In a trial, rats
had 90 sec to locate a platform; once found, rats remained on the
platform for 15 sec before being placed into a heated cage for a
30 sec ITI. This procedure was repeated for the remaining trials,
with the start arm varied for each trial. Trial 1 was considered the
information trial, as it informed the animal where the platform
was for that session. Trial 2 was considered the working memory
test trial, and trials 3–6 were considered recent memory test
trials (Frick et al., 1995). Entry into any non-platformed arm was
scored as an error, and the total number of errors were analyzed
for each trial.
Testing days were blocked into the acquisition phase (Days 1–
3) and the asymptotic phase (Days 4–7). On Day 8, animals were
given a 6-h delay between the information trial (trial 1) and the
working memory test trial to evaluate delayed memory retention.
Open Field Test
After 1 day of rest following the DMS, the OFT was performed to
assess anxiety-like behaviors. Two open field arenas, constructed
of black acrylic (100 × 100 × 40 cm), were located in adjacent
rooms with identical dimensions. The rooms were dark and
illuminated by a light bulb positioned over the center of the
chamber, illuminating the center of the open field arena at
70–80 lux. Animals were acclimated for at least 30 min in
a quiet hallway adjacent to the testing rooms. Animals were
then placed in the open field arena at the drop off location
(near the middle of the east wall) facing the center of the
arena, and allowed to roam freely for 10 min. The behavior
was videotaped for later analysis by an experimenter blind
to the treatment groups. For analysis, the arena was divided
into 25 equally-sized squares by lines created on a behavior
tracking software, Ethovision (Noldus Instruments, Leesburg,
VA). The following parameters were analyzed: time spent (sec)
in the center square and the corner squares, and total line
crossings.
Elevated Plus Maze
One day following the OFT, the EPM was given to assess anxiety-
like behaviors. The EPM consisted of four arms, 49 cm long
and 10 cm wide, elevated 50 cm off the ground. Two arms were
enclosed by walls 30 cm high, and the other two arms were
exposed and open. There were no raised enclosing edges or
barriers on the open arms. The EPM was illuminated by a light
bulb positioned over the open arms, illuminating the open arms
at 70–80 lux. Rats were placed at the junction of the open and
closed arms and allowed to explore the maze for 10min. Behavior
in the EPM was videotaped for later analysis by an experimenter
blind to the treatment groups. The amount of time spent (sec) on
the open and closed arms was analyzed.
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Forced Swim Test
One day following the EPM, the FST was conducted to assess
depressive-like behaviors. The FST was a two-day procedure.
On the first day, the rats were placed individually into a clear
Plexiglas cylinder, 30 cm high and 18 cm in diameter, containing
fresh water at 25◦C, filled up to 20 cm. The animals were left to
swim in the water for 15 min before being removed and allowed
to dry under a heat lamp in the testing cage. Twenty-four hours
later, the procedure was repeated, except the rats swam for 5
min. The videotapes of the second test day were analyzed by an
experimenter blind to the treatment groups, and the following
behaviors were scored: immobility, defined as slight movements
only necessary to keep the rat’s head above water; climbing,
defined as rapid movement of the forelimbs that break the water
surface and/or upward, vertical movement attempting to climb
against the wall; swimming, defined as all other movements.
In situ Hybridization Histochemistry
Tissue Preparation
One week following the last behavioral testing day, animals were
sacrificed by decapitation after brief exposure to isoflurane. The
brains were rapidly removed, flash frozen in 2-methylbutane
at −30◦C, and stored at −80◦C until analysis. Frozen brains
were cryosectioned at −20◦C; serial 20 µm-thick coronal
sections containing the DRN across the anteroposterior axis
were mounted on Superfrost Plus slides (Fisher Scientific
Pittsburgh, Pennsylvania) and stored at −80◦C until processed
for in situ hybridization histochemistry (ISHH). Tissue sections
were briefly thawed at room temperature and fixed in 4%
paraformaldehyde for 5 min. After rinsing in phosphate-buffered
saline (PBS), sections were treated with acetic anhydride for 10
min, dehydrated through a series of graded alcohol solutions, and
air-dried.
Oligoprobes and ISHH
Antisense oligoprobes complementary to rat and mouse
tph2 mRNA (5′-TCC GTC CAA ATG TTG TCA GGT
GGA TCC AGC CTC ACA ATG GTG GTC-3′; position
505; NM_173391) were synthesized by and purchased
from Integrated DNA Technologies (Coralville, Iowa).
The oligonucleotides were labeled with [35-S]dATP (Perkin
Elmer, Waltham, Massachusetts) at the 3′ end using terminal
deoxynucleotidyltransferase (Roche, Tucson, AZ) and purified
using the QiaQuick Nucleotide Removal kit (Qiagen, Valencia,
CA). Each slide was coverslipped with 110µl of the hybridization
buffer containing 0.1 M EDTA, SSC, single-stranded salmon
sperm DNA, torula yeast tRNA, Denhardt’s solution, formamide,
dextran sulfate, and 1M DTT. Sections were incubated in a
humidified chamber for 16 h at 42◦C. Following hybridization,
coverslips were removed and the slides were washed four
times in 1X SSC buffer for 15 min at 55◦C, once in 0.5X
SSC buffer for 20 min at room temperature, and once again
in 0.1X SSC buffer for 20 min at room temperature. Slides
were then dipped in ddH2O and air-dried. Slides were
exposed to BioMax Kodak autoradiography film in a sealed
film cassette in a dark room at room temperature for 4
days.
Densitometry and Data Analysis
The hybridization signal was quantified using ImageJ software
and correlated with behavior, as previously described (Hiroi
et al., 2006). In brief, the most intense hybridization signal
from each subregion of each brain was measured. Tissue
background within the same section of each measurement
was subtracted. An experimenter blind to the treatment
groups quantified the sections. Data are expressed in optical
density of the TpH2 autoradiographic signal in subregions of
the DRN.
Statistical Analysis
Data were analyzed separately for each behavior and brain
measure. For all measures, our primary interest was to compare
hormone treatment effects; therefore, planned comparisons were
run comparing vehicle- vs. E2- treated animals, and comparing
vehicle- vs. CEE- treated animals. For WRAM, MM, and DMS,
errors or distance were analyzed using a repeated measures
ANOVA, with Treatment as the between subjects variable, and
Day and Trial as the repeated measures within subjects variables,
as appropriate for each maze. Paired t-tests were used for the
MM probe trial analyses; for these analyses, each treatment
group was analyzed separately with percent swim distance in the
Target and Opposite quadrants as the within subjects variable.
The effects of the WRAM delay were analyzed by comparing
the errors for each memory type on Trial 3 on the last day
of testing, Day 12 (baseline), to the post-delay trial (Trial 3)
for the delay day, Day 13, for each treatment group using
the Student’s t-test. To determine whether the delay affected
performance on the DMS task, we compared errors on the
last day of testing (Day 7, baseline) to the delay day (Day
8) for the post-delay trial. For uterine weight, OFT, EPM,
FST, and TpH2 gene expression, data were analyzed using the
Student’s t-test for the aforementioned planned comparisons.
Specific behavioral parameters that showed significant treatment
effects were selected for behavior-TpH2 gene association analyses
consisting of all animals, including all treatment groups: WRAM
WMI errors from days 8–12 trial 4, DMS total errors from
days 1–3 trial 2, center time in the OFT, open arm time
in the EPM, and immobility in the FST. The Fisher’s r- to
z-test was used to analyze correlations between the specific
behavior and gene expression level in each subregion of the
DRN.
RESULTS
Uterine Weights
Both CEE- [t(14) = 6.578, p < 0.0001] and E2- [t(10) = 10.15, p
< 0.0001] treatment increased uterine weights, with both CEE
and E2 treatment groups showing greater mean weights than the
Vehicle treatment group (Figure 2). These data confirmed that
both CEE and E2 stimulated the uterine horns, as expected of
estrogenic treatments without a progestogen component.
Water Radial-Arm Maze
For the acquisition phase, there was a marginal Treatment ×
Trial interaction for the Vehicle vs. CEE comparison [F(2, 30) =
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FIGURE 2 | The effects of CEE and E2 on wet uterine weights (g) at
sacrifice. To confirm Ovx and hormone treatment, uterine tissues were
collected at sacrifice. The uterus was cut between the cervix and the ligature
at the tips of the uterine horns remaining from Ovx, and trimmed of visible fat.
The uterus was immediately weighed to obtain wet weight. Both CEE and E2
stimulated the uterus, as expected. *p < 0.0001.
2.683; p = 0.0848], with CEE animals making marginally fewer
WMC errors than Vehicle animals on trial 4, the trial with the
highest memory load [F(1, 15) = 3.223; p = 0.0928; Figure 3A].
For WMI (Figure 3B) and RM (Figure 3C), neither the CEE nor
E2 groups differed from the Vehicle group for the acquisition
phase, nor were there significant Treatment × Trial interactions
for either comparison for WMI or RM.
For the asymptotic phase, the E2 group made fewer WMI
errors than the Vehicle group [F(1, 14) = 6.409; p < 0.025];
however, the CEE group did not differ from the Vehicle group.
For WMI, there was a significant Treatment × Trial interaction
for the E2 vs. Vehicle comparison [F(3, 42) = 4.991; p < 0.005],
with the E2 group making fewer errors than the Vehicle group
on trial 4 [F(1, 15) = 5.765; p < 0.05; Figure 3E]. For WMC,
neither the CEE nor E2 groups differed from the Vehicle group
for the asymptotic phase, nor were there significant Treatment×
Trial interactions for either comparison for WMC (Figure 3D)
or RM (Figure 3F). There were no significant main effects or
interactions with Treatment for RM.
There was a delay-induced impairment for WMC errors
for the Vehicle-treated animals [t(16) = 2.968, p < 0.01]
on post-delay trial 3 (Figure 4A). In contrast, there were
no effects of the delay on WMC errors within each group
of CEE- [t(14) = 0.2837, p = 0.7808] or E2- [t(14) =
0.1.122, p= 0.2808] treated animals (Figures 4B,C, respectively),
suggesting that both hormone treatments prevented delay-
induced impairment. There were no effects of the delay on
WMI or RM errors in any of the treatment groups (data not
shown).
Morris Maze
There were no effects of CEE or E2 treatment on MM
performance across the days of testing (Figure 5A). All treatment
groups spent a higher percent of their total swim distance in the
target vs. opposite quadrant [Vehicle: t(7) = 4.864, p < 0.0025;
CEE: t(6) = 3.423, p < 0.025; E2: t(7) = 4.632, t < 0.0025],
suggesting that all groups were able to spatially localize the
platform location by the end of testing (Figure 5B).
Delayed-Matched-to-Sample
During the acquisition phase of DMS testing, collapsed across
all trials, the E2- [F(1, 15) = 6.300, p < 0.025] and CEE- [F(1, 15)
= 9.243, p < 0.01] treated animals made fewer errors than
the Vehicle-treated animals (Figure 5C). The CEE-treated group
made fewer errors than the Vehicle-treated group for the working
memory trial (trial 2) during the acquisition phase of testing
[F(1, 15) = 4.709, p < 0.05]. For recent memory trials (trials
3–6) both E2- [F(1, 15) = 5.344, p < 0.05] and CEE- [F(1, 15)
= 5.681, p < 0.05] treated groups made fewer errors than the
Vehicle-treated group.
During the asymptotic phase of DMS testing, neither the CEE
nor E2 groups differed from the Vehicle group for any analysis
(Figure 5D).
For the DMS delay trials, neither the CEE nor E2 groups
differed from the Vehicle group, as all groups, regardless
of treatment, made more errors on the trial after the delay
compared to the same trial on the baseline day [main effect
of Day for the Vehicle vs. CEE analysis: F(1, 15) = 14.415, p
< 0.0025; main effect of Day for the Vehicle vs. E2 analysis:
F(1, 15) = 19.881, p < 0.0005], with no significant Treatment
× Day interactions for this trial for either analysis (data not
shown).
Open Field Test
E2-treated animals spent more time in the center of the open
field than Vehicle-treated animals [t(14) = 2.666, p < 0.025,
Figure 6A], suggesting an E2-induced decrease in anxiety-like
behavior. E2-treated animals also spent less time in the corners
of the open field than Vehicle-treated animals [t(15) = 2.722,
p < 0.025] and CEE-treated animals [t(14) = 2.393, p < 0.05;
Figure 6B]. CEE-treated animals also tended to spend more time
in the center than Vehicle-treated animals [t(14) = 2.123, p =
0.0521]. There were no effects of E2 or CEE on total distance
traveled (Figure 6C), indicating that overall locomotion was not
affected by the estrogen treatments. Collectively, these results
suggest that E2 treatment decreased anxiety-like behaviors in the
OFT, without affecting overall locomotion.
Elevated Plus Maze
E2-treated animals spent more time in the open arms of the EPM
than Vehicle-treated animals [t(10) = 2.821, p < 0.025]; CEE-
treated animals also spent more time in the open arms than the
Vehicle-treated animals [t(10) = 2.476, p < 0.05], suggesting that
both CEE and E2 treatment are related to decreased anxiety-like
behavior in the EPM (Figure 6D). Although E2-treated animals
also tended to spend less time in the closed arms of the EPM than
the Vehicle-treated animals, this difference was marginal [t(11) =
1.934, p= 0.0792], and there were no effects of CEE on time spent
in the closed arms of the EPM (Figure 6E).
Forced Swim Test
E2-treated animals spent less time immobile in the FST than
Vehicle-treated animals [t(14)= 2.294, p< 0.05, Figure 6F]. CEE-
treated animals also tended to spend less time immobile than the
Vehicle-treated animals, although this difference was marginal
[t(14) = 1.811, p = 0.0916, Figure 6F]. There were no effects of
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FIGURE 3 | The effects of CEE and E2 on the water radial arm maze (WRAM). Errors committed during the Acquisition Phase (days 2–7) for (A) working
memory correct (WMC), (B) working memory incorrect (WMI), and (C) reference memory (RM). Errors committed during the Asymptotic Phase (days 8–12) for (D)
WMC, (E) WMI, and (F) RM. *p < 0.05, #p < 0.10.
either estrogen on time spent swimming or climbing (data not
shown).
TpH2 In situ Hybridization Histochemistry
Seven DRN subregions were analyzed separately (Figure 7): the
rostral DRN included the (1) dorsomedial and (2) ventromedial
DRN (rDM and rVM, respectively); the mid DRN included the
(3) dorsolateral, (4) dorsomedial, and (5) ventromedial DRN
(mDL, mDM, mVM, respectively); the caudal DRN included
the (6) dorsomedial and (7) ventromedial DRN (cDM, cVM,
respectively). Two halves of the mDL and cDM subregions were
averaged and used as one value for each subregion.
Rostral DRN
CEE treatment increased the TpH2 mRNA signal in the rDM
[t(13) = 2.727, p < 0.025] and in the rVM [t(13) = 2.233, p <
0.05], compared to Vehicle treatment (Figures 8A,B). There were
no effects of E2 on TpH2 mRNA in either the rDM or rVM
(Figures 8A,B).
Mid DRN
There were no effects of CEE or E2 on TpH2 mRNA in the
mDM, compared to Vehicle treatment (Figure 8C). In contrast,
E2 treatment increased TpH2 mRNA in the mVM [t(15) = 2.598,
p< 0.025] and in themDL [t(15)= 2.502, p< 0.025], compared to
Vehicle treatment (Figures 8D,E). There were no effects of CEE
on TpH2 mRNA in either the mVM or mDL (Figures 8D,E).
Caudal DRN
There were no effects of CEE or E2 on TpH2 mRNA in the
cDM, compared to Vehicle treatment (Figure 8F). In contrast,
both CEE [t(13) = 2.205, p < 0.05] and E2 [t(13) = 2.904, p <
0.025] increased TpH2 mRNA in the cVM, compared to Vehicle
treatment (Figure 8G).
Correlation Between TpH2 Gene
Expression and Behavior
Table 1 lists the correlation matrix, highlighting significant
correlations, between TpH2 mRNA levels in distinct subregions
of the DRN and behavioral measures from all animals, regardless
of treatment.
Rostral DRN
In the rDM, there was a negative correlation between TpH2
mRNA levels and total errors in the DMS [r(21) = −0.4328, p <
0.05; Figure 9A], suggesting that higher levels of TpH2 in this
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FIGURE 4 | The effects of CEE and E2 on the water radial arm maze
(WRAM) delay task. Working memory correct (WMC) errors committed by
the vehicle (A), CEE (B), or E2 (C) groups during the post-delay trial (T3)
following a 4-h delay between trials 2 and 3 on day 13. *p < 0.01.
region are associated with better performance in this task. There
was also a positive correlation between TpH2mRNA levels in the
rDM and open arm time in the EPM [r(15) = 0.6631, p < 0.005;
Figure 9B], indicating that animals with higher levels of TpH2
in this region tend to have decreased anxiety-like behaviors in
the EPM. In the rVM, there was a negative correlation between
TpH2 mRNA levels and immobility in the FST [r(19) = −0.4858,
p< 0.05; Figure 9C], indicating that higher levels of TpH2 in this
region are associated with decreased depressive-like behaviors.
Mid DRN
In the mDL, there was a positive correlation between TpH2
mRNA levels and center time in the OFT [r(21) = 0.5116, p <
0.025; Figure 9D], suggesting that higher levels of TpH2 in this
region are associated with decreased anxiety-like behaviors in
the OFT. In the mVM, there was a positive correlation between
TpH2 mRNA levels and center time in the OFT [r(21) = 0.4265;
p < 0.05; Figure 9F], suggesting that higher levels of TpH2 in
this region are associated with decreased anxiety-like behaviors
in the OFT. However, it is noteworthy that these two particular
positive correlations may primarily result from one E2 treated
animal with the highest center time (i.e., the far right data point
in Figures 9D,F), as the two correlations become null when this
data point is removed from analysis. Yet, this data point was
not a statistical outlier and therefore was left in the analysis.
Interpretation should be made with careful consideration of
this caveat. We also found a positive correlation between TpH2
mRNA levels in the mDM and open arm time in the EPM [r(16)
= 0.5300; p < 0.025; Figure 9E], indicating that higher levels of
TpH2 are associated with decreased anxiety-like behaviors in the
EPM.
Caudal DRN
We found a positive correlation between TpH2 mRNA levels in
the cVM and open arm time in the EPM [r(15) = 0.5199, p <
0.05; Figure 9G], suggesting that higher levels of TpH2 in this
region are associated with decreased anxiety-like behaviors in
the EPM. There was also a negative correlation between TpH2
mRNA levels in the cVM and immobility in the FST [r(18) =
−0.4664, p < 0.05; Figure 9H], indicating that higher levels of
TpH2 in this region are associated with decreased depressive-like
behaviors.
DISCUSSION
The present study was designed to compare the effects of two
commonly used estrogens in HT, CEE and E2, on a battery of
cognitive, anxiety-like, and depressive-like behaviors. We also
investigated the nature of the subregion-specific relationships
between the brain 5-HT system and the evaluated behaviors.
Although both hormone treatments generally had beneficial
effects on the assessed behaviors, CEE and E2 treatments resulted
in a number of hormone-specific effects with regard to the degree
of the improvement, depending on the type of behavior. These
differential behavioral effects may be reflected by the distinct
impact of CEE vs. E2 on the brain serotonergic system, as we
report subregion-specific effects on TpH2 mRNA expression
in the DRN. Finally, we demonstrate here subregion-specific
relationships between the DRN TpH2 mRNA and each of the
evaluated behaviors, giving credence to the idea that select 5-HT
output from the distinct subregions of the DRN may be involved
in modulating different aspects of cognitive vs. anxiety-like vs.
depressive-like behaviors.
Beneficial Cognitive Effects of CEE and E2
Treatments are Dependent on Multiple
Factors
The current findings add to the growing evidence that estrogens
can have beneficial effects on cognition across different age
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FIGURE 5 | The effects of CEE and E2 on the Morris maze (MM) and delayed-match-to-sample (DMS) behaviors. (A) Swim distance (cm) in the MM for
days 1–5. (B) Percent swim distance in the target vs. opposite quadrants in the MM for the probe trial assessment. Total errors committed on DMS during (C) the
Acquisition Phase (days 1–3) and (D) the Asymptotic Phase (days 4–7). *p < 0.05.
groups and rat strains. For instance, in rats, the beneficial effects
of estrogens have been demonstrated across the lifespan ranging
from young-adult, middle-aged, to aged timeframes, as well as
across various strains of rats, including Sprague Dawley (Luine
et al., 1998; Sandstrom and Williams, 2001; Korol and Kolo,
2002), Purdue-Wistar (Bimonte and Denenberg, 1999), Long-
Evans (Daniel et al., 1997; Markham et al., 2002; Rodgers et al.,
2010), and Fischer-344 (Bimonte-Nelson et al., 2003a, 2006;
Acosta et al., 2010; Engler-Chiurazzi et al., 2011).
It is important to note, however, that whether the beneficial
effects of estrogens are realized may be dependent on multiple
factors. First, our findings, not surprisingly, based on the state
of the literature, demonstrate that the effects of estrogens are
task- and memory domain- dependent. We report here that
the estrogen treatments differentially enhanced performance on
the WRAM, depending on the type of learning and memory.
Specifically, we found that CEE, but not E2, tended to enhance
working memory on the trials with the highest memory load
during the acquisition phase, but not the latter, asymptotic phase
of testing in the WRAM task for WMC. In contrast, E2, but not
CEE, improved working memory on the trials with the highest
memory load during the latter phase of testing in the WRAM
task forWMI. Together, these results suggest that while cognitive
benefits of CEE appeared early in the acquisition, or learning,
phase of testing, E2 had an impact on working memory later
in the asymptotic phase of testing. When challenged with a
more demanding extended temporal retention component of the
WRAM task, both CEE and E2 treatments in the present study
improved memory retention across a 4-h delay. Although the
present study is the first to our knowledge to report benefits
of E2 administration in female rats in delayed recall of this
specific task, E2 treatment has been previously shown to improve
memory retention of a DMS version of the Morris water maze
task after a 30- and 100- min retention interval in young adult
Ovx Sprague Dawley rats (Sandstrom and Williams, 2001, 2004).
Similarly, E2 also enhanced performance during 1 min and 3 h
delay trials of a land version of an eight-arm radial maze (Bohacek
and Daniel, 2007). Further corroborating the beneficial cognitive
effects of estrogens on memory retention, our laboratory has
also previously reported a post-delay protection with the same
dose of CEE treatment in middle-aged Ovx Fischer-344 rats
(Acosta et al., 2010; Engler-Chiurazzi et al., 2011). Delayed recall
challenges the animals with a demanding task and involves
retention of information over an intermediate range of time
between short- and long- term memory processing. We also
found that the benefits of estrogens were observed only on the
trials with the highest memory load. Taken together, we speculate
that the benefits of estrogens are more readily manifested when
animals are challenged with a difficult task.
In contrast to our previous study showing that CEE-treated
middle-aged Ovx animals made fewer reference memory errors
in the latter phase of testing than those given vehicle (Acosta
et al., 2010), the current study did not find an effect of CEE
on reference memory during any phase of WRAM testing. It is
important to note that the present study was conducted in young
rats, whereas middle-aged rats were used in the previous study
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FIGURE 6 | The effects of CEE and E2 on anxiety-like and depressive-like behaviors. Time spent in the center (A) and corners (B) and total distance traveled
(C) in the open field test (OFT). Time spent in the open arms (D) and the closed arms (E) of the elevated plus maze (EPM). Time spent immobile (F) in the forced swim
test (FST). *p < 0.05, #p < 0.10.
by Acosta et al. (2010). Given that there is a marked decline in
memory around middle-age (Markowska, 1999; Talboom et al.,
2008, 2014), the age difference between the two studies likely,
at least in part, accounts for the different results across studies.
Specifically, compared to the young adult rats evaluated in the
present study, it is possible that themiddle-aged animals from the
previous study exhibited worse reference memory performance
due to an age-related decline in baseline cognitive abilities,
which interacted with a cognitive impact of estrogen. Human
research corroborates this concept; for instance, the WHIMS
results showed that estrogen treatment had the greatest influence
in women with the lowest baseline cognitive scores (Coker et al.,
2009). Another study also showed that premenopausal cognitive
ability largely explained the adverse effects of menopause on
cognition (Kok et al., 2006). Collectively, these studies suggest
that the degree to which the cognitive effects of estrogen are
manifested partially depends on baseline cognitive abilities.
In addition to memory types, task difficulty, and baseline
cognitive abilities, hormone administration regimen also plays an
important role inmodulating the cognitive outcome of estrogens.
Using an intermittent administration regimen (i.e., 2 days on
and 2 days off), the present study using Sprague Dawley rats
revealed beneficial effects of both CEE and E2 treatments onDMS
performance during the acquisition phase. Our laboratory has
previously shown similar enhancements in DMS performance
using the same intermittent regimen of CEE treatment in
middle-aged Ovx Fischer-344 rats (Acosta et al., 2009). On
the other hand, a tonic CEE treatment via an osmotic pump
impaired, rather than enhanced, performance in the same DMS
task (Engler-Chiurazzi et al., 2011). Therefore, the intermittent
estrogen treatment regimen may pose an advantage over the
tonic regimen with respect to cognitive function as tested on
the DMS task. Indeed, a previous study also showed enhanced
spatial memory performance with a biweekly intermittent E2
treatment compared to tonic treatment (Bimonte-Nelson et al.,
2006). Intermittent E2 treatments have been shown to enhance
performance on a delayed match-to-position T-maze task in Ovx
rats (Gibbs, 2000), and a spatial working memory task in Ovx
rhesus monkeys (Rapp et al., 2003) as well. In agreement with
the idea that intermittent administration has favorable cognitive
outcomes, cognitive responsiveness to tonic E2 treatment was
enhanced when primed with E2 (Markowska and Savonenko,
2002). It is also noteworthy that in a previous study, an
intermittent E2 treatment did not have an effect onmortality rate,
whereas a tonic E2 treatment dramatically increased mortality
rate, in middle-aged Ovx rats (Bimonte-Nelson et al., 2006),
suggesting an improved safety profile with the intermittent
regimen over the tonic regimen. Although the underlying
mechanism for this difference is unclear, evidence suggests that
chronic vs. acute injections of estrogens lead to differential
estrogen receptor content and dynamics, with acute injections
resulting in rapid degradation followed by gradual replenishment
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FIGURE 7 | Subregional anatomy of the raphe nuclei. Top panels show the schematic diagrams (Paxinos and Watson, 1986) and middle panels show the
representative photomicrographs of the subregions analyzed for TpH2 in situ hybridization signal in rostral, mid, and caudal levels of the midbrain raphe from each
treatment group. Ovals and a triangle are shown on the bottom panels to illustrate the subregions analyzed for the densitometry. DRN, dorsal raphe nucleus; DM,
dorsomedial; VM, ventromedial; DL, dorsolateral.
of estrogen receptors (Kassis and Gorski, 1981; Sato et al.,
1983; Rosser et al., 1993). This receptor recycling may have
important consequences of E2 actions on physiology, feedback
mechanisms, and ultimately, behavior. Given that the half-life
of E2 is about 2 hours (Kassis and Gorski, 1981), it is possible
that the intermittent regimen of 2 days on and off used in
the present study would result in a receptor recycling profile
impacting behavior. Future studies investigating the profile of
estrogen receptor recycling status may reveal important insights
into the underlying mechanism for the present reported findings.
Other important factors that impact the cognitive outcome
of estrogens include duration and dose of estrogen treatment,
as well as the menopause status of the animals. There is some
evidence showing that a non-acute, chronic E2 treatment is
required for a beneficial outcome in rats. As demonstrated by
Luine et al. (1998), 12 days, but not 3 days, of E2 treatment
improved choice accuracy in an eight arms baited radial-arm
maze paradigm. Dose of estrogen also plays an important role.
For instance, compared to the 30 µg CEE dose, lower doses
of CEE (12 and 24 µg) had no protective effects on memory
retention (Engler-Chiurazzi et al., 2011). Furthermore, although
30 µg CEE had beneficial effects on memory retention in
Ovx rats, this retention benefit was not found in transitionally
menopausal rats treated with the same dose of CEE (Acosta
et al., 2010), suggesting that menopause status impacts whether
protective effects are realized.
Given that both CEE and E2 can be metabolized into weaker
estrogens, such as estrone, the interaction between different types
of estrogens may be a critical factor in predicting the extent,
and in some cases the direction, of the cognitive outcomes. To
illustrate the impact of estrogen ratios on cognition, we have
previously shown that the dose-dependent effects of CEE on
working memory were related to the differences in resulting
circulating ratios of estrone to E2 (Engler-Chiurazzi et al.,
2011). Specifically, the lowest dose of CEE had no protective
effects and it increased serum estrone without changing E2
levels. In contrast, the higher dose of CEE that enhanced
cognitive performance resulted in increased serum levels of
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FIGURE 8 | The effects of CEE and E2 on TpH2 mRNA in the subregions of the DRN. TpH2 mRNA in situ hybridization signal in the rostral (A) dorsomedial
(rDM) and (B) ventromedial (rVM); medial (C) dorsomedial (mDM), (D) ventromedial (mVM), and (E) dorsolateral (mDL); caudal (F) dorsomedial (cDM), and (G)
ventromedial (cVM) DRN. Each bar represents the mean ± SEM TpH2 optical density. *p < 0.05.
TABLE 1 | Correlation matrix (Pearson r) between behavioral measures and TpH2 mRNA in distinct subregions of the DRN.
Correlation coefficient (Pearson r) TPH2 rDM TPH2 rVM TPH2 mDL TPH2 rDM TPH2 mVM TPH2 cDM TPH2 cVM
WMI errors WRAM −0.087 −0.119 −0.306 0.003 −0.281 −0.178 −0.255
Total errors DMS −0.433* −0.219 0.232 0.013 0.062 −0.025 −0.303
Center time OFT 0.412# 0.267 0.512** 0.310 0.427* 0.320 0.432#
Open arm time EPM 0.663*** 0.136 0.432 0.530** 0.269 0.413# 0.523*
Immobility FST −0.363 −0.486* −0.184 −0.053 −0.141 −0.228 −0.466*
*** p < 0.01, **p < 0.025, *p < 0.05, #p < 0.1 using Fisher’s r to z test. Bold values denote statistical significance of p < 0.05.
estrone as well as E2. In addition, we have reported that
continuous estrone treatment impaired spatial memory in Ovx
rats (Engler-Chiurazzi et al., 2012). These studies, collectively,
imply that elevated levels of estrone in the simultaneous absence
of moderate E2 levels can lead to detrimental cognitive effects.
Of note, there is evidence that E2 can have detrimental cognitive
effects when not metabolized to estrone. For example, we
recently examined the cognitive effects of ethinyl estradiol (EE),
a synthetic form of E2 used in oral contraceptives, which cannot
be converted to weaker estrogens. We found that a daily dose
of EE (0.3 µg) impaired multiple domains of memory in Ovx
rats (Mennenga et al., 2015). Together, these studies suggest
that exogenous administration of estrogens can have significant
interactions with the circulating levels of its metabolites to impact
behavior, depending on the ratio of distinct estrogens.
The importance of considering hormone interactions extends
to other ovarian hormones and their synthetic counterparts.
In particular, progestins are prescribed in women to offset the
risks associated with the use of unopposed estrogens, including
venous thromboembolism, stroke, endometrial hyperplasia, and
Frontiers in Neuroscience | www.frontiersin.org 13 December 2016 | Volume 10 | Article 517
Hiroi et al. Estrogens, Brain Serotonin, and Behavior
FIGURE 9 | Correlation between TpH2 mRNA in the subregions of DRN and cognitive, anxiety-like, and depressive-like behaviors. Significant correlations
using the Fisher’s r- to z-test between TpH2 mRNA in the (A) rDM and total errors in the delayed-match-to-sample (DMS) task, (B) rDM and open arm time in the
elevated plus maze (EPM), (C) rVM and immobility in the forced swim test (FST), (D) mDL and center time in the open field test (OFT), (E) mDM and open arm time in
the EPM, (F) mVM and center time in the OFT, (G) cVM and open arm time in the EPM, and (H) cVM and immobility in the FST.
endometrial cancer (Smith et al., 1975; Ziel and Finkle, 1975;
Mørch et al., 2016; Swanepoel et al., 2016). Compared to estrogen
alone, combined estrogen and progestin treatment can have
distinct cognitive effects, depending on multiple factors (for
review, please see Acosta et al., 2013). Therefore, a careful
assessment of the different HT formulations, and how these
exogenous hormones interact with the endogenous hormone
milieu in women, may yield personalized options that have a safer
physiological risk profile with improved cognitive outcomes.
In summary, the herein findings suggest that a careful
consideration of parameters such as type of memory,
administration regimen, menopausal status, and type of
estrogens is warranted when evaluating the cognitive effects of
estrogens. Over the years, there have been numerous review
articles underscoring the importance of these factors (Gibbs
and Gabor, 2003; Brinton, 2004; Bimonte-Nelson et al., 2010;
Rocca et al., 2011; Maki, 2012; Sherwin, 2012; Acosta et al., 2013;
Chisholm and Juraska, 2013; Fischer et al., 2014; Luine, 2014;
Koebele and Bimonte-Nelson, 2015; McCarrey and Resnick,
2015). The present study adds to the growing consensus that
clarity gained from understanding the impact of these parameters
is critical for providing information to offer unique and tailored
treatment options for women.
E2 and, to a Lesser Extent, CEE
Treatments Decreased Anxiety-Like and
Depressive-Like Behaviors
The benefits of estrogen treatments extended to anxiety-like
behaviors.We showed that E2 decreased anxiety-like behaviors in
the OFT and EPM, consistent with published literature (Nomikos
and Spyraki, 1988; Lund et al., 2005, 2006; Hiroi et al., 2006;
Hiroi and Neumaier, 2006). However, the anxiolytic effects of
CEE may not be as robust as those of E2; although CEE tended
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to have anxiolytic effects, especially in the EPM, it did not
reach statistical significance in the OFT in the current study.
Previous research evaluating the effects of CEE on anxiety-like
behaviors also revealed inconsistent anxiolytic effects; research
has demonstrated that CEE decreased anxiety-like behaviors in
the EPM, but not in the OFT, using middle-aged ovary-intact rats
(Walf and Frye, 2008). Another study from the same laboratory
showed that CEE decreased anxiety-like behaviors both in the
OFT and EPM, although the anxiolytic effects depended on the
reproductive status of the rats (Frye et al., 2010). Specifically,
this study reported that the anxiolytic effects of CEE were
found in rats maintaining normal reproductive status (i.e., 4–
5 days estrous cycle, fertility, and fecundity), but not in rats
with declining reproductive status (i.e., those that were acyclic
and/or in constant diestrus or estrus, became pregnant on fewer
than 60% of the occasions that they were mated, and had litters
with fewer than 10 pups; Frye et al., 2010). It is possible that
the use of an Ovx model, resulting in a profile of abrupt and
declined reproductive status, in the present study contributed to
the diminished anxiolytic effects with CEE treatment in some
measures of anxiety evaluated herein. Nevertheless, these results
suggest that the reproductive status of the animals could be an
important determinant in modulating the estrogen regulation of
anxiety.
We also found that E2 and, to a lesser extent, CEE treatments
had antidepressant-like effects, as measured by decreased
immobility in the FST. Although previous studies have shown
antidepressant-like effects of E2 (Estrada-Camarena et al., 2003;
Walf et al., 2004), this study is the first to our knowledge to
demonstrate that, like E2, CEE also has some antidepressant
properties. These findings in the rodent model are consistent
with clinical evidence demonstrating the beneficial effects of
CEE- or E2- containing HT on mood (Zweifel and O’Brien,
1997; Gleason et al., 2015). However, perhaps not unexpectedly,
there are numerous parameters impacting the antidepressant
effects of estrogen therapy, including menopausal status and a
previous history of depression. Rubinow and colleagues reported
in a systematic review of 24 randomized, placebo controlled
trials, that the antidepressant efficacy of E2 was supported
in perimenopausal depressed women, but not postmenopausal
women or non-depressed women (Rubinow et al., 2015). Thus,
further studies to reveal the specific factors and underlying
mechanisms influencing the antidepressant effects of estrogens
are crucial to our understanding of the nuanced effects of HT on
mood.
CEE and E2 Treatments Differentially
Increased DRN TpH2 mRNA in a
Region-Specific Manner
To begin to elucidate the underlying mechanisms of estrogens on
the evaluated behaviors, we examined TpH2 mRNA expression
levels with a particular focus on the subregions of the DRN. It
is well established that estrogen stimulates brain 5-HT activity
(see Rubinow et al., 1998 for review); in particular, E2 increased
TpH2 mRNA in select subregions of the DRN (Hiroi et al.,
2006), and these increases in the particular subregions were
critical for the anxiolytic effects of E2 (Hiroi et al., 2006,
2011). The subregions of the DRN enable distinct responses
to diverse stimuli, as these subregions are recognized to have
distinct inputs from, and projections to, diverse forebrain regions
involved in the regulation of different aspects of behaviors
(Imai et al., 1986; Vertes, 1991; Lowry, 2002). In addition to
the distinct neurocircuitry, cells in the DRN subregions have
unique morphology and phenotypes (Lowry, 2002). Of relevance,
the two major types of estrogen receptors, ERα and ERβ,
have differential expression patterns in the DRN subregions
(Shughrue et al., 1997; Alves et al., 1998; Lu et al., 2001; Liu
et al., 2002; Lindberg et al., 2003; Matthews and Gustafsson,
2003), enabling subregion-specific responses to different types of
estrogens.
Given this subregion specificity of ER distribution, it is not
surprising that we found region-specific effects of CEE vs. E2 on
DRN TpH2 expression. We report here that E2 increased TpH2
mRNA in the mid and caudal, but not the rostral, subregions
of the DRN, corroborating previous reports (Hiroi et al., 2006;
Donner and Handa, 2009). In contrast, CEE increased TpH2
mRNA in the rostral and caudal, but not the mid, subregions of
the DRN. The distinct expression patterns of ERα and ERβ in the
DRN subregions may underlie a potential direct mechanism for
the differential patterns of CEE- vs. E2- induced upregulation of
TpH2 mRNA. Within the DRN, ERα are expressed in the non-
serotonergic neurons preferentially in the rostral DRN (Alves
et al., 1998). In contrast, ERβ are expressed in the serotonergic
neurons of the mid and caudal DRN (Shughrue et al., 1997;
Lu et al., 2001). The primary estrogen component of CEE is
estrone, which has a unique pattern of ER binding affinity
compared to that of E2 (Sitruk-Ware, 2002; Kuhl, 2005). Thus,
further investigations to elucidate the role of region-specific ER
expression inmediating estrogen effects on TpH2 expressionmay
shed light on underlying mechanisms.
Region-Specific Associations Between
TpH2 mRNA and Distinct Behaviors
In order to assess the relationships between TpH2 gene
expression in the DRN and cognitive, anxiety-like, and
depressive-like behaviors, we correlated the level of TpH2mRNA
in each subregion of the DRN with the evaluated behaviors. We
found select associations between TpH2 mRNA and behavior,
depending on the subregion and the type of behavior. A previous
study showed that higher levels of TpH2 mRNA in the caudal
DRN were associated with less anxiety-like behavior in the
OFT (Hiroi et al., 2006); the current study also found this
association. We demonstrated here that animals with higher
TpH2 expression in the caudal DRN tended to exhibit decreased
anxiety-like behaviors in two rodent tests of anxiety, the OFT
and the EPM, suggesting that higher levels of TpH2 expression
in the caudal DRN are associated with an anxiolytic profile.
The importance of the caudal DRN in mediating the anxiolytic
effects of E2 has also been highlighted in a previous study, as the
anxiolytic effects of E2 were blocked or mimicked by a targeted
TpH2 knockdown or overexpression, respectively, in the caudal
DRN (Hiroi et al., 2011).
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Here, we also report significant associations between
depressive-like behaviors and TpH2 mRNA in select subregions
of the DRN.We found that TpH2mRNA selectively in the rostral
and caudal, but not the mid, DRN was negatively correlated
with the time spent immobile in the FST; thus, animals with
higher TpH2 mRNA in these subregions of the DRN tended to
exhibit reduced depressive-like behaviors. The neurons from
the rostral DRN preferentially project to forebrain regions, such
as neocortex, striatum, and substantia nigra, and are thought
to be important for behavioral arousal after stress. On the
contrary, the caudal DRN neurons preferentially project to
limbic regions, such as ventral hippocampus, lateral septum,
and locus coeruleus, and are important for the regulation of
emotional coping (Vertes, 1991; Vertes et al., 1999; Lowry,
2002). Therefore, the recruitment of the rostral and caudal
subregions of the DRN may help modulate important aspects
of depressive-like behaviors, such as stress-response and coping
strategies, required to produce an appropriate response to a
stressful environment.
Cognitive behaviors also had region-selective associations
with TpH2 in the current study. Indeed, we showed here that
TpH2 mRNA selectively in the rostral, but not mid or caudal,
DRN was negatively correlated with total errors made on the
working memory trial (trial 2) of the DMS cognitive task,
indicating that animals with higher TpH2 mRNA in the rostral
DRN tended to exhibit better working memory performance.
Compared to the caudal DRN, the rostral DRN projects more
densely to virtually all neocortical regions (Vertes, 2004), which
are regarded as the most recently evolved brain regions and
are thought to be important for processing higher cognitive
functions in mammals, such as spatial reasoning. Specifically,
the frontal cortex may be an important region regulating spatial
abilities in rodents and humans (Poucet, 1990; Poucet and
Herrmann, 1990; Miotto et al., 1996; Bimonte-Nelson et al.,
2003a). Therefore, activation of 5-HT activity from the rostral
DRN may modulate cognitive performance in the DMS task via
altering the cortical activity in regions such as the frontal cortex.
It is noteworthy that we found that CEE, but not E2, increased
TpH2 mRNA in the rostral subregions of the DRN, suggesting
that the CEE-induced enhancement of DMS performance may
be, in part, mediated by this increase in rostral DRN TpH2.
However, the associations between the behaviors and TpH2
reported in the current study are correlational, and further
studiesmanipulating these variables are required to confirm these
assertions.
Clinical Implications
The present findings are in agreement with the human literature
suggesting an intricate relationship between estrogen and the
brain serotonergic system, and indicating that this interaction
plays an important role in regulating behavior. Decreased 5-HT
activity is associated with menopause (Halbreich et al., 1995),
as well as cognitive and mood disorders (Sun et al., 2004;
Garcia-Alloza et al., 2005; You et al., 2005; Mowla et al., 2007;
Noristani et al., 2011; Waider et al., 2011). The beneficial
cognitive andmood effects of estrogen-containing HT and agents
that enhance serotonergic neurotransmission, such as selective
serotonin reuptake inhibitors (SSRI), have been demonstrated
(Campbell and Whitehead, 1977; Best et al., 1992; Ohkura
et al., 1995; Arpels, 1996; Gregoire et al., 1996; Gleason et al.,
2015). These studies support the hypothesis that estrogens
ameliorate the symptoms of cognitive and mood disorders by,
in part, restoring brain 5-HT activity. The present study further
highlights the importance of regional specificity as a parameter
to uncover the relationships amongst hormones, the serotonergic
system, and behavior. Specifically, we found that CEE and E2
increased TpH2 mRNA in distinct subregions of the DRN, and
that these increases in TpH2 were associated with improved
cognitive performance, decreased anxiety-like behaviors, and
decreased depressive-like behaviors, in a region-specific manner.
This region specificity is likely key to further unravel the complex
relationships between hormones, the brain serotonergic system,
and regulation of distinct aspects of behaviors.
CONCLUSION
In summary, the present study found that estrogen treatment
had beneficial effects on cognitive, anxiety-like, and depressive-
like behaviors, corroborating clinical reports; however, the effects
depended on specific parameters. As CEE is becoming less
popular and bioidentical hormones, such as E2, are increasingly
gaining popularity and are prescribed more frequently now
in the post-WHI era, the findings reported here provide a
timely analysis of the differential effectiveness of CEE vs. E2.
Although both CEE and E2 exerted beneficial effects, the
efficacy of the treatments depended on the distinct behavior.
Moreover, whether the beneficial cognitive effects of estrogens
were observed was impacted by task difficulty. More robust
protective effects were found when animals were challenged with
a more demanding task. Compared to CEE, E2 generally had
more robust anxiolytic and antidepressant effects. The hormone-
specific effects on anxiety- and depressive- like behaviors
further underscore the assertion that the beneficial effects
of these hormones depend on the demands of the task;
for example, the FST may induce a higher stress response
compared to the OFT and EPM, and this could impact the
efficacy of estrogens. These behavioral effects of CEE and
E2 were accompanied by a differential impact on the DRN
5-HT system depending on the subregion, highlighting the
importance of evaluating these subregions to understand the
intricate relationships between 5-HT activity and different
types of behavior. Indeed, we demonstrated that CEE and
E2 increased TpH2 gene expression with remarkable region
specificity. We found that E2 increased TpH2 mRNA in the
mid and caudal DRN, while CEE increased TpH2 mRNA
in the rostral and caudal DRN, suggesting a hormone- and
region- specific enhancement of the capacity to make more
5-HT in these regions, thereby potentially increasing the
serotonergic output to the select forebrain projection areas.
These region-selective increases in TpH2 may have important
regulatory functions, as we also found that the associations
between each behavior and TpH2 depended on the distinct
DRN subregion. Deciphering serotonergic involvement in the
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regulation of these behaviors is critical, as it may provide
non-hormonal options to treat adverse symptoms of menopause.
Non-hormonal options, such as the recently FDA-approved
use of the SSRI paroxetine for vasomotor symptoms in
menopausal women, present alternatives for women who have
contraindications for the use of HT. Therefore, further studies
to detail the specific serotonergic neurocircuitry involved in
cognition vs. anxiety vs. mood, and how estrogens modulate
these relationships, may lead to novel, non-hormonal avenues of
tailored treatment for individuals suffering from cognitive and
affective disorders.
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